Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016055950) COMBINATION OF HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2016/055950 International Application No.: PCT/IB2015/057664
Publication Date: 14.04.2016 International Filing Date: 07.10.2015
IPC:
A61K 39/245 (2006.01) ,C07K 16/08 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
245
Herpetoviridae, e.g. herpes simplex virus
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08
against material from viruses
Applicants:
NOVARTIS AG; Lichtstrasse 35 CH-4056 Basel, CH
Inventors:
FEIRE, Adam; US
PANG, Yinuo; US
PERTEL, Peter; US
YU, Jing; US
Common
Representative:
NOVARTIS AG; Lichtstrasse 35 CH-4056 Basel, CH
Priority Data:
62/061,37808.10.2014US
62/204,65313.08.2015US
Title (EN) COMBINATION OF HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES
(FR) COMBINAISON D'ANTICORPS DE NEUTRALISTION DU CYTOMÉGALOVIRUS HUMAIN
Abstract:
(EN) The disclosure relates to the use of a combination of antibodies or antigen binding fragments thereof to hCMV; and to dosages, ratios and minimum trough serum concentrations of the antibodies. The combination is useful for the neutralization of hCMV, for example, in pregnant, immunocompromised 5 or immunosuppressed patients undergoing bone marrow and organ transplants with a low occurrence of viral resistance.
(FR) L'invention concerne l'utilisation d'une combinaison d'anticorps ou de leurs fragments de liaison d'antigène à hCMV ; et des dosages, des rapports et des concentrations sériques de creux minimales d'anticorps. La combinaison est utilisée pour neutraliser hCMV, par exemple, chez des patientes en état grossesse, immunidéficientes ou immunodéprimées subissant des transplantations de moelle osseuse et d'organes avec une faible apparition de résistance virale.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)